Every student project that touches a lyophilised compound begins with a paper exercise: the briefing pack a supervisor reads and signs off before any bench work starts. Mistakes at that stage are rarely dramatic — a borrowed phrase here, a mislabelled appendix there — but they matter, because a research peptide and a licensed medicine sit in entirely different regulatory categories. The notes below are aimed at students and materials managers in UK laboratories who need the documentation to be defensible the first time, without overstating what a supplier has actually provided.
Why the Category Question Comes Before the Chemistry
A licensed medicine arrives with a marketing authorisation and a defined documentary set: summary of product characteristics, patient information leaflet, stated indications and posology. A research-use-only material arrives with none of that, and the absence is the point. Research Sciences, the UK supplier, describes its catalogue as strictly for controlled laboratory and analytical research, and states that none of its products should be regarded, described, marketed, repackaged, supplied or used as medicines, medical devices, injectables, treatments or food supplements under UK law. The company further states that it does not supply products for therapeutic, clinical or diagnostic purposes. Those are the supplier’s published positions, not legal advice, and they should be quoted as such in a briefing pack.
The practical consequence for a student is a wording problem before it is a scientific one. Clinical vocabulary migrates easily into draft protocols — dose, administration, treatment group, patient sample, therapeutic window — and each of those terms implies an intention the material is not supplied for. A supervisor reading “dose” in a protocol for an in-vitro assay will usually ask for the sentence to be rewritten, because the correct descriptors are concentration, exposure condition, aliquot volume and assay response. The same applies to headings in slide decks and to the aims section of the project brief. Where a student genuinely needs to explain why a compound is studied, the framing should stay within published research context — receptor binding, signalling pathways, analytical characterisation — rather than any implied clinical application.
It is also worth recording, in the briefing itself, that the purchaser carries responsibility for lawful use, safe handling, storage and disposal, and for compliance with relevant UK regulations including COSHH and laboratory safety standards. That line belongs in the risk assessment and in the induction record, not buried in an appendix. Finally, the shop’s labelling is described in its FAQs as “For Research Use Only – Not for Human Consumption”, presented as being in line with MHRA guidance. A student should present that as the supplier’s stated position and understand that the materials are not for human or veterinary use at any point in the workflow.
Anatomy of the Documents: Labels, CoAs and the Reference Numbers That Tie Them Together
What the vial label actually tells you
Research Sciences labels use a reference format that combines the SKU code with an expiry date, for example BPC10-03/27, and that reference links to the corresponding certificate of analysis. Students should transcribe the full reference into the project’s materials register rather than abbreviating it, because it is the string the shop asks for when documentation is queried. It is equally important to note what the label does not tell you: the site’s FAQs state that vial cap colours and other packaging may vary, and that cap colour is not an indicator of identity, analytical quality or manufacturing origin. A briefing pack that lists “blue-capped vials” as an identifying feature is describing packaging, not a material.
What the CoA tells you, and what it does not
The FAQs state that a certificate of analysis is provided for every product, covering purity and identity by HPLC, and that compounds are made by international partners using solid-phase peptide synthesis before final verification and quality checks in the UK. The About page describes a full-spectrum testing framework covering purity, identity, heavy metals and endotoxin evaluation. The homepage lists “CoAs Janoshik Analytical Reports”, and that is as far as the claim should be repeated: a researcher should open the CoA that accompanies the specific batch. Headline figures such as “≥99% Verified Purity” or “UK Research Materials Over 99.1% Purity” are the shop’s published wording and should be reconfirmed on the live site and against the batch CoA at the time of ordering, not copied into a report as though independently audited.
Two further caveats belong in the briefing. First, the FAQs explain that restocked products may carry the same Internal Test Reference as earlier stock; an ITR links to associated sample testing reports but does not confirm that separate deliveries come from the same production lot or have had separate independent testing. Second, all peptides contain trace amounts of mannitol as an excipient, and the shop does not supply blended peptides, recommending that compounds be bought individually and combined only within a controlled experimental design. When the reference list is compiled, cite the catalogue entry by name and SKU alongside the analytical document — a Peptide uk listing for MT-1 10mg or BPC-157 10mg is only meaningful in project paperwork when the batch CoA is filed with it.
Assembling the Briefing Pack: A Document-by-Document Checklist
The briefing pack should open with a one-page scope statement confirming that the work is in-vitro, that the materials are research-use-only, and that they are not for human or veterinary use. From there, a wording audit of the protocol is the fastest way to catch category errors: replace clinical terms with laboratory ones, remove any implied therapeutic endpoint, and check that every figure attributed to the supplier is either quoted as published wording or replaced with the value on the batch CoA.
Storage and handling statements should follow the supplier’s quick guide. Lyophilised peptides are stored at −20°C or below, sealed with desiccant and protected from moisture, heat and light, with repeated freeze–thaw cycles avoided. Vials are allowed to reach room temperature before opening, work is carried out in a clean environment, and only the amount required for the experiment is removed. Reconstituted material is less stable and is held at 2–8°C for short-term laboratory use. Reconstitution itself should be written strictly as an in-vitro step — diluent volume, target concentration for the assay, mixing technique — and any mention of the supplier’s free reconstitution calculator must carry the caveat that it is for laboratory research use only and must never be used for human or veterinary dosing.
Procurement records should name the shop, the SKU, the label reference and the CoA filing location, and should note the supplier’s current published fulfilment terms for reconfirmation at checkout: orders dispatched the next working day, Royal Mail Tracked 24 as the described service with delivery estimates that may vary, and no returns once dispatched except for damage, incorrect supply or quality issues under the Refunds & Returns Policy. Homepage lines such as “24hr UK Delivery”, “3,000+ UK Orders” and “7 Days Expert Customer Support” are marketing statements published at the time of writing and should be treated as such. A short waste and disposal paragraph, a competency sign-off and a dated review line complete the pack — and the RUO statement should appear on every version circulated, including slides.
Lyon pastry chemist living among the Maasai in Arusha. Amélie unpacks sourdough microbiomes, savanna conservation drones, and digital-nomad tax hacks. She bakes croissants in solar ovens and teaches French via pastry metaphors.